日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

MDS 对阿扎胞苷的临床反应与 HSPC 中独特的 DNA 甲基化变化有关

Thoms Julie A I, Yan Feng, Hampton Henry R, Davidson Sarah, Joshi Swapna, Saw Jesslyn, Sarowar Chowdhury H, Lim Xin Ying, Nunez Andrea C, Kakadia Purvi M, Bhuyan Golam Sarower, Zou Xiaoheng, Nguyen Mary, Ghodousi Elaheh S, Koch Forrest C, Vafaee Fatemeh, Thompson I Richard, Karimi Mohammad M, Pickford Russell, Raftery Mark J, Hough Sally, Buckland Griselda, Bailey Michelle, Ghodke Yuvaraj, Absar Noorul, Vaughan Lachlin, Pasalic Leonardo, Fong Chun Y, Kenealy Melita, Hiwase Devendra K, Stoddart Rohanna I, Mohammed Soma, Lee Linda, Passam Freda H, Larsen Stephen R, Spring Kevin J, Skarratt Kristen K, Rebeiro Patricia, Presgrave Peter, Stevenson William S, Ling Silvia, Tiley Campbell, Fuller Stephen J, Roncolato Fernando, Enjeti Anoop K, Hoenemann Dirk, Lemech Charlotte, Jolly Christopher J, Bohlander Stefan K, Curtis David J, Wong Jason W H, Unnikrishnan Ashwin, Hertzberg Mark, Olivier Jake, Polizzotto Mark N, Pimanda John E

A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors

一项针对既往接受过治疗的HER2阳性晚期实体瘤患者的新型抗HER2抗体药物偶联物GQ1001的Ia期研究

Zhou, Chenfei; Wang, Bin; Teng, Christina; Yang, Hui; Piha-Paul, Sarina A; Richardson, Gary; Malalasekera, Ashanya; Sun, Yajun; Wang, Wei; Liu, Jieqiong; Shi, Yan; Zhan, Xianbao; Lemech, Charlotte

Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study

通过一项前瞻性多中心非随机队列研究评估澳大利亚早期临床试验中的患者多样性

Nindra, Udit; Tang, Joanne; Hong, Jun Hee; Hong, Martin; Teng, Christina; Wei, Joe; Killen, Andrew; Cooper, Adam; Wilkinson, Kate; Ng, Weng; Lemech, Charlotte; Chua, Wei; Pal, Abhijit

Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER

早期肿瘤临床试验中健康相关生活质量的前瞻性评估:PEARLER

Nindra, Udit; Tang, Joanne; Hong, Jun Hee; Descallar, Joseph; Hong, Martin; Killen, Andrew; Dubey, Priyadarshini; Attaullah, Jeneen; Scott, Grace; Cooper, Adam; Wilkinson, Kate; Pal, Abhijit; Teng, Christina; Roohullah, Aflah; Wei, Joe; Ng, Weng; Lemech, Charlotte; Chua, Wei

A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration

一项随机、双盲、两治疗、两周期、交叉设计的I期研究,旨在比较健康志愿者单次静脉注射60 IU/Kg Abcertin和Cerezyme后的药代动力学、安全性和耐受性。

Kang, Eungu; Kim, Dohyung; Hwang, Soojin; Lemech, Charlotte; Wharton, Jessica; Lee, Yongyoon; Yoo, Han Wook; Lee, Beom Hee

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

ivonescimab (AK112/SMT112)(一种抗PD-1/VEGF-A双特异性抗体)在晚期实体瘤患者中的1a期剂量递增研究

Frentzas, Sophia; Austria Mislang, Anna Rachelle; Lemech, Charlotte; Nagrial, Adnan; Underhill, Craig; Wang, Wenjing; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu; Coward, Jermaine I G

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

一项针对转移性去势抵抗性前列腺癌的Acapatamab(一种半衰期延长、靶向PSMA的双特异性T细胞衔接剂)的I期研究

Dorff, Tanya; Horvath, Lisa G; Autio, Karen; Bernard-Tessier, Alice; Rettig, Matthew B; Machiels, Jean-Pascal; Bilen, Mehmet A; Lolkema, Martijn P; Adra, Nabil; Rottey, Sylvie; Greil, Richard; Matsubara, Nobuaki; Tan, Daniel S W; Wong, Alvin; Uemura, Hiroji; Lemech, Charlotte; Meran, Johannes; Yu, Youfei; Minocha, Mukul; McComb, Mason; Penny, Hweixian Leong; Gupta, Vinita; Hu, Xuguang; Jurida, Gabor; Kouros-Mehr, Hosein; Janát-Amsbury, Margit M; Eggert, Tobias; Tran, Ben

Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology

鼻内TLR2/6激动剂INNA-051的评价:安全性、耐受性和药理学验证

Mercuri, Francesca A; White, Scott; McQuilten, Hayley A; Lemech, Charlotte; Mynhardt, Stephan; Hari, Rana; Zhang, Ping; Kruger, Nicole; McLachlan, Grant; Miller, Bruce E; West, Nicholas P; Tal-Singer, Ruth; Demaison, Christophe

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

更正:CXCR2拮抗剂navarixin联合pembrolizumab治疗特定晚期实体瘤:一项II期随机试验

Armstrong, Andrew J; Geva, Ravit; Chung, Hyun Cheol; Lemech, Charlotte; Miller, Wilson H Jr; Hansen, Aaron R; Lee, Jong-Seok; Tsai, Frank; Solomon, Benjamin J; Kim, Tae Min; Rolfo, Christian; Giranda, Vincent; Ren, Yixin; Liu, Fang; Kandala, Bhargava; Freshwater, Tomoko; Wang, Judy S

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

CXCR2拮抗剂navarixin联合pembrolizumab治疗特定晚期实体瘤:一项II期随机试验

Armstrong, Andrew J; Geva, Ravit; Chung, Hyun Cheol; Lemech, Charlotte; Miller, Wilson H Jr; Hansen, Aaron R; Lee, Jong-Seok; Tsai, Frank; Solomon, Benjamin J; Kim, Tae Min; Rolfo, Christian; Giranda, Vincent; Ren, Yixin; Liu, Fang; Kandala, Bhargava; Freshwater, Tomoko; Wang, Judy S